EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis

Ou Yu iD, Mengyao Lu, Terence K Y Lai, Margaret Hahn, Sri Mahavir Agarwal iD, Brian O'Donoghue, Bjørn H Ebdrup, Dan Siskind iD

Therapeutic Advances in Psychopharmacology · 2024-01 · 14

DOI: 10.1177/20451253241255476 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 30.05.2024. Verfasst von Ou Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Queensland, Mayne Medical School, 20 Weightman St, Herston, QLD 4006, Australia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antipsychotic medications are associated with weight gain and metabolic derangement. However, comprehensive evidence for the efficacy of co-commenced pharmacological treatments to mitigate initial weight gain is limited. Metformin has been shown to be effective in reducing weight among people on antipsychotic medications who are already overweight, but the potential benefits of metformin co-commencement in mitigating antipsychotic-induced weight gain has not been systematically reviewed.

Method

We conducted a systematic review of PubMed, EMBASE, PsychInfo, CINAHL, the Cochrane database, and China National Knowledge Infrastructure from inception to 18 November 2023. We undertook a meta-analysis of concomitant commencement of metformin versus placebo for attenuation of weight gain and metabolic syndrome for people with schizophrenia commencing a new antipsychotic.

Results

Fourteen studies from Australia, United States, Venezuela, and China with 1126 participants were included. We found that metformin was superior to placebo in terms of attenuating weight gain (−3.12 kg, 95% CI −4.22 to −2.01 kg). Metformin also significantly attenuated derangement of fasting glucose levels, total cholesterol, and total triglyceride levels. Sensitivity analysis on study quality, duration, and antipsychotic agent did not impact the results. Meta-analysis was also conducted on adverse drug reactions (ADR) reported in each study which showed no significant difference in ADR incidence between metformin and placebo groups. Subgroup analysis on antipsychotic-naïve participants and participants switching to new antipsychotic did not impact the results.

Conclusion

Metformin led to statistically significant and clinically meaningful attenuation of weight gain as well as attenuation of several other metabolic parameters when commenced concomitantly with antipsychotic medications. Co-commencement of metformin with antipsychotic medications, where tolerated, should be considered in the clinical setting with aim to improve long-term cardiometabolic outcomes for patients with long-term need of antipsychotic treatments.

Schlagwörter

Stichwörter der Autor:innen

antipsychoticsmetabolic syndromemetforminobesityschizophrenia

Autor:innen und Institutionen

  • Faculty of Medicine, University of Queensland, Mayne Medical School, 20 Weightman St, Herston, QLD 4006, Australia.
  • Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Addiction and Mental Health Service, Metro South Health, Brisbane, QLD, Australia.
  • Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.
  • Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
  • Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: Ou Yu, Sri Mahavir Agarwal, Dan Siskind

Zitieren

APA

Yu, O., Lu, M., Lai, T. K. Y., Hahn, M., Agarwal, S. M., O'Donoghue, B., Ebdrup, B. H., & Siskind, D. (2024). Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology, 14. https://doi.org/10.1177/20451253241255476

Vancouver

Yu O, Lu M, Lai TKY, Hahn M, Agarwal SM, O'Donoghue B, et al. Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology. 2024;14. doi:10.1177/20451253241255476

BibTeX
@article{Yu2024,
  author = {Yu, Ou and Lu, Mengyao and Lai, Terence K Y and Hahn, Margaret and Agarwal, Sri Mahavir and O'Donoghue, Brian and Ebdrup, Bjørn H and Siskind, Dan},
  title = {Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis},
  journal = {Therapeutic Advances in Psychopharmacology},
  year = {2024},
  volume = {14},
  doi = {10.1177/20451253241255476}
}
Kostenlos starten →